Actively Recruiting
Evaluating the Safety, Tolerability, and Immune Response of the Personalized NeoOVIV mRNA Vaccine with Chemotherapy and PD-1 Antibody in Women With Stage II or III Ovarian Cancer After Surgery
Led by West China Hospital · Updated on 2026-09-09
9
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, immune response, and early clinical effects of NeoOVIV, a personalized mRNA-lipid nanoparticle vaccine, in patients with stage II or III ovarian cancer after surgery. This Phase I, open-label, single-arm trial also studies the vaccine combined with standard chemotherapy and a PD-1 antibody called tislelizumab. The study uses a dose-escalation design to find the best vaccine dose while monitoring for side effects. Participants will receive standard chemotherapy starting about 4 weeks after surgery. Tislelizumab will begin around 10 weeks after surgery and be given for four doses, usually one day before chemotherapy cycles. The NeoOVIV vaccine is personalized using tumor tissue and blood samples, identifying specific tumor neoantigens through genetic testing. Vaccination starts about 10 weeks after surgery with nine total doses four priming doses during chemotherapy every three weeks, then five weekly booster doses after chemotherapy. Three vaccine dose levels 25, 50, and 100 micrograms will be tested with 3 to 6 participants per dose. Participants will be closely monitored for side effects such as injection-site reactions, fever, fatigue, immune-related events, and serious organ toxicities. Blood tests will assess immune responses, including T-cell and B-cell activity. The study will also explore clinical outcomes like disease-free survival, tumor marker changes, imaging results, and circulating tumor DNA for minimal residual disease. Follow-up will continue after treatment to track long-term safety, survival, and disease recurrence, with total monitoring lasting up to 24 months after surgery.
CONDITIONS
Brief Title
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery
Research Team
N
Nan Lin, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here